Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 28, 2017

DrugPatentWatch Database Preview

RIVASTIGMINE TARTRATE Drug Profile

« Back to Dashboard

What is the patent landscape for Rivastigmine Tartrate, and what generic alternatives are available?

Rivastigmine Tartrate is a drug marketed by Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd. and is included in nine NDAs.

The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the rivastigmine tartrate profile page.

Summary for Tradename: RIVASTIGMINE TARTRATE

Patents:0
Applicants:9
NDAs:9
Suppliers / Packagers: see list14
Bulk Api Vendors: see list72
Clinical Trials: see list88
Patent Applications: see list1,606
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RIVASTIGMINE TARTRATE at DailyMed

Pharmacology for Tradename: RIVASTIGMINE TARTRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orchid Hlthcare
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL090879-004Jun 10, 2015ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL204572-004Mar 25, 2016ABRXNoNo► Subscribe► Subscribe
Alembic Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL091689-001Jun 12, 2012ABRXNoNo► Subscribe► Subscribe
Orchid Hlthcare
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL090879-001Jun 10, 2015ABRXNoNo► Subscribe► Subscribe
Watson Labs
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077129-001Jan 8, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot